BioSig Technologies, Inc. (BSGM) |
|
0.5141 -0.02 (-3.69%)
|
09-27 09:59 |
|
Open: |
0.5211 |
Pre. Close: |
0.5338 |
|
High:
|
0.5567 |
Low:
|
0.514 |
|
Volume:
|
31,036 |
Market Cap:
|
40(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 9:45:10 AM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 0.8 One year: 0.93 |
| Support: |
Support1: 0.51 Support2: 0.4 |
| Resistance: |
Resistance1: 0.68 Resistance2: 0.8 |
| Pivot: |
0.5 |
| Moving Average: |
MA(5): 0.57 MA(20): 0.51
MA(100): 0.97  MA(250): 0.87 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 53.1 %D(3): 63 |
| RSI: |
RSI(14): 48.9 |
| 52-week: |
High: 1.64 Low: 0.25 |
| Average Vol(K): |
3-Month: 794 (K) 10-Days: 232 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BSGM ] has closed below upper band by 28.2%. Bollinger Bands are 21.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.58 - 0.58 |
0.58 - 0.59 |
|
Low:
|
0.53 - 0.53 |
0.53 - 0.53 |
|
Close:
|
0.53 - 0.53 |
0.53 - 0.54 |
|
Company Description |
|
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut. |
Headline News |
Wed, 30 Aug 2023
The Cooper Companies (COO) Q3 Earnings Match Estimates - Nasdaq
Thu, 24 Aug 2023
BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals - Yahoo Finance
Thu, 20 Jul 2023
BioSig picked for NVIDIA-backed Inception program for AI - Seeking Alpha
Thu, 20 Jul 2023
BioSig AI Sciences Selected for NVIDIA Inception Partnership Program to Support R&D Collaboration on AI Medical Device Platform for Hospitals - Yahoo Finance
Wed, 12 Jul 2023
Artificial Intelligence In Healthcare: A Potentially Strong Opportunity For BioSig Technologies (NASDAQ: - Benzinga
Thu, 29 Jun 2023
BioSig Joins Webull Corporate Connect - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
0 (M) |
| Shares Float |
77 (M) |
|
% Held by Insiders
|
6.308e+007 (%) |
|
% Held by Institutions
|
17.4 (%) |
|
Shares Short
|
2,560 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.143e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-11 |
|
Return on Assets (ttm)
|
555.6 |
|
Return on Equity (ttm)
|
-291.3 |
|
Qtrly Rev. Growth
|
275000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-625.81 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-0.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-20 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.56e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
